Harris (HRS) Forms $157.72 Double Top; Cymabay Therapeutics (CBAY) Shorts Lowered By 2.37%

Cymabay Therapeutics Inc (NASDAQ:CBAY) had a decrease of 2.37% in short interest. CBAY’s SI was 2.06M shares in March as released by FINRA. Its down 2.37% from 2.11M shares previously. With 1.08M avg volume, 2 days are for Cymabay Therapeutics Inc (NASDAQ:CBAY)’s short sellers to cover CBAY’s short positions. The SI to Cymabay Therapeutics Inc’s float is 6.37%. The stock increased 4.68% or $0.67 during the last trading session, reaching $14.99. About 872,831 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since March 11, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Harris Corporation (HRS) formed double top with $170.34 target or 8.00% above today’s $157.72 share price. Harris Corporation (HRS) has $18.73B valuation. The stock increased 1.27% or $1.98 during the last trading session, reaching $157.72. About 483,428 shares traded. Harris Corporation (NYSE:HRS) has risen 39.09% since March 11, 2017 and is uptrending. It has outperformed by 22.39% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $831.15 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, January 10 by Oppenheimer. H.C. Wainwright maintained it with “Buy” rating and $1200 target in Monday, July 17 report. Cantor Fitzgerald initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, September 19. Cantor Fitzgerald has “Buy” rating and $16.0 target. H.C. Wainwright maintained the stock with “Neutral” rating in Wednesday, January 4 report. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray on Wednesday, January 31. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Thursday, January 25 by Roth Capital. H.C. Wainwright downgraded Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, June 1. H.C. Wainwright has “Neutral” rating and $2.25 target. H.C. Wainwright upgraded the stock to “Buy” rating in Monday, January 30 report. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Monday, July 17. Piper Jaffray has “Buy” rating and $6.5000 target. The firm earned “Buy” rating on Monday, September 11 by Piper Jaffray.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.10, from 0.99 in 2017Q2. It increased, as 33 investors sold Harris Corporation shares while 196 reduced holdings. 78 funds opened positions while 148 raised stakes. 99.32 million shares or 1.40% less from 100.73 million shares in 2017Q2 were reported. Paloma Prns Management owns 12,873 shares or 0.02% of their US portfolio. Blb&B Advisors Ltd Liability Corporation stated it has 0.04% of its portfolio in Harris Corporation (NYSE:HRS). Alabama-based Oakworth Cap has invested 0.08% in Harris Corporation (NYSE:HRS). Peapack Gladstone Finance reported 0.2% of its portfolio in Harris Corporation (NYSE:HRS). 4,400 were accumulated by Highvista Strategies Limited Liability Com. Atlantic Trust Ltd Liability Com reported 14,759 shares. Blue Chip Partners has invested 0.12% in Harris Corporation (NYSE:HRS). Pennsylvania Tru reported 8,768 shares stake. Shamrock Asset Mngmt Llc invested 0.77% in Harris Corporation (NYSE:HRS). Rhumbline Advisers stated it has 0.06% of its portfolio in Harris Corporation (NYSE:HRS). Natixis, a France-based fund reported 53,962 shares. State Street has 4.76 million shares for 0.05% of their portfolio. Capital Inv Advsrs holds 0.04% or 3,992 shares. Ahl Ptnrs Llp accumulated 0.07% or 28,473 shares. Wells Fargo & Mn has 0.22% invested in Harris Corporation (NYSE:HRS).

Among 10 analysts covering Harris (NYSE:HRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Harris had 36 analyst reports since August 10, 2015 according to SRatingsIntel. Jefferies maintained Harris Corporation (NYSE:HRS) rating on Wednesday, November 1. Jefferies has “Buy” rating and $157 target. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 3. Jefferies maintained it with “Buy” rating and $13500 target in Friday, July 14 report. The stock of Harris Corporation (NYSE:HRS) earned “Outperform” rating by RBC Capital Markets on Monday, October 12. Jefferies maintained Harris Corporation (NYSE:HRS) on Monday, September 18 with “Buy” rating. The company was maintained on Tuesday, June 6 by Jefferies. The stock of Harris Corporation (NYSE:HRS) has “Buy” rating given on Wednesday, January 31 by Seaport Global. The rating was upgraded by JP Morgan to “Overweight” on Monday, October 12. The company was initiated on Thursday, December 17 by Jefferies. The firm has “Outperform” rating given on Monday, November 7 by Cowen & Co.

Analysts await Harris Corporation (NYSE:HRS) to report earnings on May, 2. They expect $1.64 earnings per share, up 18.84% or $0.26 from last year’s $1.38 per share. HRS’s profit will be $194.72M for 24.04 P/E if the $1.64 EPS becomes a reality. After $1.67 actual earnings per share reported by Harris Corporation for the previous quarter, Wall Street now forecasts -1.80% negative EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: